Zenflow Presents BREEZE™ Trial Results at AUA 2026

Zenflow, Inc. presented data from its BREEZE™ pivotal clinical trial at the AUA annual meeting, showcasing the effectiveness and safety of the Zenflow Spring® Implant and Delivery System for treating benign prostatic hyperplasia (BPH). The trial results indicated a 60% responder rate after one year and highlighted high patient satisfaction and low rates of adverse events. The data support the recent FDA approval of the device, which offers a flexible and patient-friendly solution for BPH symptoms without the typical surgical barriers.